The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. To coincide with the publication of the DDW eBook ‘Antibody discovery:… Read More
Promontory Therapeutics has treated its first patients in France as part of the ongoing Phase II clinical trial of PT-112 in patients with late-stage metastatic castration-resistant prostate cancer (mCRPC). The Phase II proof-of-concept study has the objective of characterising the benefit-risk ratio and selecting the optimal… Read More
News round-up for 24-28 July by DDW Digital Content Editor Diana Spencer. To coincide with the publication of the DDW eBook ‘Antibody discovery: Breakthroughs accelerating therapeutic antibodies’, our news highlights this week all focus on antibodies, particularly the recommendation by the EU’s CHMP… Read More
Lineage Cell Therapeutics and Cancer Research UK have announced encouraging primary and secondary endpoint results from their clinical study of VAC2 in advanced non-small cell lung cancer (NSCLC). Five of eight patients treated (62.5%) had a best response of immune-related stable disease, and three (37.5%) demonstrated… Read More
A potent anti-cancer therapy has been created using Nobel prize-winning “click chemistry”, in a new study by University College London (UCL) and Stanford University researchers. The study, published in Nature Chemistry, opens up new possibilities for how cancer immunotherapies might be built in… Read More
Immuno-oncology company Crescendo Biologics has revealed plans to augment the ongoing Phase Ib clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major existing shareholders, including Sofinnova… Read More
A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The Phase I clinical trial, sponsored and managed by Cancer Research UK’s Centre for Drug Development, tested whether… Read More
Listen to this article on the DDW Podcast: DDW’s Megan Thomas spoke with Frédéric Triebel, the French immunologist/oncologist who is best known for his 1990 discovery of the LAG-3 immune control mechanism. Triebel shares insights from his career, expands on his experience with the company he founded, Immutep, and comments on the… Read More
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorisation of JZP458 (a recombinant Erwinia asparaginase or crisantaspase). It has been recommended for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic… Read More
The EU Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of conditional marketing authorisation for epcoritamab (Tepkinly) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The final… Read More
Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. Under the terms of the agreement, Cancer Research Horizons will license Twist’s ‘Library of Libraries’, a collection of synthesised antibody libraries designed based on naturally occurring sequences that… Read More
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation for Janssen’s Talvey (talquetamab). The drug has received a positive opinion for use as a monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who… Read More
Germo Gericke, Ariceum Therapeutics, tells DDW's Megan Thomas about his work in radiopharmaceuticals for the treatment of cancer and offers valuable advice to others in this field. 1. Where do you work, and can you tell us what you’re working on at the moment? I am the Chief Medical Officer… Read More
Listen to this article on the DDW Podcast: Evan Floden, CEO of Seqera Labs examines how data sharing platforms are impacting cancer and genomics research. The tide has been turning in the worlds of diagnostics and drug development. Bioinformatics and genetic sequencing are starting to be placed front and centre of… Read More
Listen to this article on the DDW Podcast: Rolf Turk, Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Since its discovery in 2012, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionised the biomedicine and cell and gene therapy fields,… Read More
The European Medicines Agency (EMA) has accepted for regulatory review Astellas Pharma’s marketing authorisation application (MAA) for zolbetuximab, an investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody. The application is for authorisation as a first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose… Read More
